NCT05222165
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 3 Years and older (Child, Adult, Older Adult))
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior treatment of a FGFR1-3 selective inhibitor
https://ClinicalTrials.gov/show/NCT05222165